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MaOBJECTIVES The aim of this study was to assess the impact of ticagrelor dosing regimens on pharmacodynamic (PD)
proﬁles in patients on maintenance ticagrelor therapy.
BACKGROUND Many patients on maintenance P2Y12-inhibiting therapies may require coronary revascularization pro-
cedures, raising a common clinical question with regard to the dosing regimen of the P2Y12-inhibiting agent to be used.
To date, investigations assessing dosing regimens of P2Y12 receptor inhibitors in patients on maintenance therapy have
been only assessed with thienopyridines, but not with ticagrelor.
METHODS This was a prospective, randomized, double-blind, placebo-controlled study assessing the PD effects of
2 dosing regimens of ticagrelor in patients on standard aspirin and ticagrelor maintenance therapy. A total of 60 patients
were randomized to either 90 mg (maintenance dose [MD] group) or 180 mg (loading dose [LD] group) dose of tica-
grelor. PD assessments were conducted at 3 time points (baseline, 1 h and 4 h). PD assessments were deﬁned according
to the platelet reactivity index (PRI) (vasodilator-stimulated phosphoprotein phosphorylation assay), P2Y12 reaction
unit (VerifyNow P2Y12 assay) and adenosine diphosphate–induced platelet aggregation by light transmittance
aggregometry.
RESULTS There were no differences in baseline levels of platelet reactivity with all assays. Intergroup comparisons by
means of repeated-measures analysis adjusted for baseline PRI values showed that the LD group had signiﬁcantly
lower PRI levels compared with the MD group during the overall study time course (p ¼ 0.031). Consistent ﬁndings
were found for P2Y12 reaction unit (p ¼ 0.026) and light transmittance aggregometry (p ¼ 0.004). Intragroup com-
parisons showed that a more prompt and sustained platelet inhibitory effect was achieved more consistently with an LD
regimen compared with a MD regimen.
CONCLUSIONS In patients on maintenance ticagrelor therapy, a 180-mg LD regimen of ticagrelor is associated with more
potent and prompt platelet inhibition compared with a 90-mgMD. (Impact of Ticagrelor Re-Load Pharmacodynamic Proﬁles;
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome
ADP = adenosine diphosphate
ANCOVA = analysis of
covariance
ANOVA = analysis of variance
DAPT = dual antiplatelet
therapy
LD = loading dose
LTA = light transmittance
aggregometry
MD = maintenance dose
PCI = percutaneous coronary
intervention
PD = pharmacodynamic
PRI = platelet reactivity index
PRU = P2Y12 reaction units
VASP = whole-blood
vasodilator-stimulated
phosphoprotein
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1076D ual antiplatelet therapy (DAPT)with aspirin and a P2Y12 receptor in-hibitor is the recommended therapy
for secondary prevention of ischemic events
in patients with acute coronary syndrome
(ACS) and those patients undergoing percuta-
neous coronary interventions (PCIs) (1–3).
Ticagrelor represents a new class of oral non-
thienopyridine P2Y12 receptor inhibitor, called
a cyclopentyltriazolo-pyrimidine. Compared
with clopidogrel, ticagrelor has reversible
binding properties and more prompt and
potent pharmacodynamic (PD) effects as well
as less variability in interindividual response
(4–7). In a large-scale clinical trial of ACS pa-
tients, ticagrelor was associated with a signif-
icant reduction in ischemic events, including
cardiovascular mortality, compared with clo-
pidogrel at 12 months (8). Such beneﬁt was
observed irrespective of management strat-
egy (invasive or noninvasive) and occurred
without any differences in overall majorbleeding complications, although noncoronary artery
bypass graft bleeding events were increased with tica-
grelor. Despite such beneﬁt, recurrent atherothrom-
botic events still occur in ticagrelor-treated patients
who may also require PCI (8,9). Moreover, many pa-
tients receiving maintenance ticagrelor therapy may
need revascularization because of coronary athero-
sclerotic disease progression or for staged PCI (10,11).
Numerous investigations have been conducted to
deﬁne the dosing regimen associated with more
favorable PD effects in patients on maintenance
P2Y12-inhibiting therapy using thienopyridines
(12–17). In particular, reloading patients on mainte-
nance clopidogrel therapy is associated with addi-
tional platelet inhibition (12–14). This was also
demonstrated among prasugrel-treated patients,
suggesting that a sizable number of P2Y12 receptors
remain uninhibited during maintenance therapy even
with a more potent agent (15,16). However, there are
substantial differences in the pharmacological prop-
erties between ticagrelor and thienopyridines (4–7),
and whether PD proﬁles vary according to the dosing
regimen administered in patients on maintenance
ticagrelor therapy remains unexplored. Therefore, we
conducted a study to assess the PD effects of different
ticagrelor dosing regimens in patients on ticagrelor
maintenance therapy.
METHODS
STUDY POPULATION AND RESEARCH DESIGN.
This was a prospective, randomized, double-blind,placebo-controlled PD study conducted in patients
on maintenance ticagrelor therapy (NCT01731041).
All patients had experienced an ACS and a guideline-
based indication to be on DAPT with aspirin and
ticagrelor (1–3). Patients were screened at the Divi-
sion of Cardiology of the University of Florida Col-
lege of Medicine – Jacksonville. All patients were
eligible for the study if they were between 18 and
80 years of age and if they were receiving treatment
with low-dose aspirin (<100 mg/day) and ticagrelor
(90 mg/bid) for at least 14 days as part of their
standard treatment regimen. Exclusion criteria
included history of intracranial bleeding, severe he-
patic impairment (hepatic enzymes >2.5 times the
upper limit of normal), active bleeding or propensity
to bleed, recent (<14 days) antiplatelet treatment
with a glycoprotein IIb/IIIa antagonist, platelet count
<80  106/ml, hemodynamic instability, glomerular
ﬁltration rate <30 ml/min, on treatment with any
oral anticoagulant, patients with sick sinus syn-
drome or second- or third-degree atrioventricular
block without pacemaker protection, drugs inter-
fering with CYP3A4 metabolism (ketoconazole, itra-
conazole, voriconazole, clarithromicin, nefazodone,
ritonavir, saquinavir, nelﬁnavir, indinavir, atazana-
vir, and telithromizycin), hemoglobin <10 g/dl, and
pregnant and lactating females.
Using a computer-based randomization system,
patients were randomized in a 1:1 fashion to 1 of 2
treatment groups: 1) 90-mg dose of ticagrelor (main-
tenance dose [MD] group); 2) 180 mg of ticagrelor
(loading dose [LD] group). Patients randomized to the
MD group received 1 ticagrelor 90-mg tablet and 1
matching placebo tablet. Patients randomized to the
LD group received 2 ticagrelor 90 mg tablets. Tica-
grelor 90-mg tablets and matching placebo were
provided by AstraZeneca (Wilmington, Delaware).
Investigators, laboratory personnel, and patients
were blinded to treatment assignments. PD assess-
ments were performed at 3 time points using 3
different assays as described in the following. After
completing the study, patients resumed their stan-
dard ticagrelor 90 mg twice-daily dosing regimen at
their scheduled times. Adverse events, including
bleeding, bradyarrhythmias, and dyspnea, were re-
corded (8). Patients received a follow-up phone call
the following day to conﬁrm that no adverse events
had occurred.
BLOOD SAMPLING AND PLATELET FUNCTION ASSAYS.
Blood samples were collected at 3 time points at
baseline (while on maintenance ticagrelor therapy)
and at 1 h and 4 h after randomized treatment.
Baseline blood samples were collected 12  2 h after
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1077the last MD of ticagrelor to assess trough levels of
platelet reactivity (18). At each time point, PD as-
sessments were conducted using 3 different platelet
function assays: whole-blood vasodilator-stimulated
phosphoprotein (VASP), VerifyNow system (VN-
P2Y12), and light transmittance aggregometry (LTA)
(7,15,18). In brief, VASP phosphorylation was
measured by quantitative ﬂow cytometry using
commercially available labeled monoclonal anti-
bodies according to standard protocols (Biocytex Inc.,
Marseille, France) and quantiﬁed by the platelet
reactivity index (PRI). The VN-P2Y12 assay (Accriva,
San Diego, California) measures platelet-induced
aggregation as an increase in light transmittance
and reports results in P2Y12 reaction units (PRUs). LTA
was conducted using platelet-rich plasma by the
turbidimetric method in a 2-channel aggregometer
(Chrono-Log 490 Model, Chrono-Log Corp., Haver-
town, Pennsylvania) after 20 mM adenosine dip-
hosphate (ADP) stimuli and the percentage of
aggregation recorded at 6 min.
SAMPLE SIZE CALCULATION AND STUDY ENDPOINTS.
The primary endpoint of the study was the compar-
ison in the PRI determined by VASP between baseline
and 4 h after dosing in each arm of treatment.
Assuming an absolute 10% difference in VASP-PRI
between baseline and 4 h with a common SD of
14%, 28 patients need to be enrolled in each arm to
obtain a 95% power and a 2-sided alpha of 0.05.
Considering a possible dropout rate of w5% to 10%,
we estimated that a total of 60 patients needed to
be randomized to ensure that complete data would
be available for analysis. A cutoff of 10% absolute
change in PRI was chosen because this has been
associated with a 44% relative reduction of throm-
botic events in patients undergoing PCI (19). Addi-
tional analysis assessing intergroup and intragroup
PD differences using the VN-P2Y12 and LTA were
also conducted.
STATISTICAL ANALYSIS. Conformity to the normal
distribution was evaluated for continuous variables
with the Kolmogorov-Smirnov test. For baseline
characteristics, continuous variables are expressed as
mean  SD or median (interquartile range) where
appropriate, and categorical variables are expressed
as frequencies and percentages. The Student t test or
Mann-Whitney U test was used to compare contin-
uous variables where appropriate. The chi-square or
Fisher exact test (if expected value in any cell was <5)
were used to compare categorical variables between
the 2 groups. The comparison of platelet reactivity at
baseline was performed with a univariate analysis of
variance with a general linear model. An analysis ofcovariance (ANCOVA) method with a general linear
model, using the baseline value of platelet reactivity
as a covariate, was used to evaluate all other
between-group comparisons. A mixed between-
within subjects ANCOVA was conducted with a gen-
eral linear model to assess the impact of the 2
different treatments on platelet reactivity across
time points using baseline platelet reactivity levels
as covariate. A repeated-measures analysis of vari-
ance (ANOVA) model was used to evaluate intra-
group comparisons. A 2-tailed p value <0.05 was
considered to indicate a statistically signiﬁcant dif-
ference for all the analyses performed. Results are
reported as least-square mean  SE for these
detailed analyses. Statistical analysis was performed
using SPSS version 22.0 software (SPSS Inc., Chicago,
Illinois).RESULTS
PATIENT POPULATION. Between January 2013 and
April 2014, a total of 106 patients with a previous
ACS on maintenance ticagrelor therapy were iden-
tiﬁed. Of these, 65 patients provided written con-
sent to participate in the study; 5 patients withdrew
after screening. Therefore, a total of 60 patients on
maintenance ticagrelor 90 mg bid therapy were
included. These patients were randomized to either
a 90 mg (n ¼ 30; MD group) or 180 mg (n ¼ 30;
LD group) dose of ticagrelor. Patient disposition
is summarized in Figure 1. Baseline characteristics
of the study population are summarized in Table 1.
There were no differences in baseline charac-
teristics between groups. No adverse events were
reported.
PHARMACODYNAMIC FINDINGS.
Whole-B lood Vasodilator-Stimulated Phospho-
protein–Platelet Reactivity Index. There were no
signiﬁcant differences between groups in baseline
platelet reactivity as assessed by VASP-PRI (p ¼
0.350). Repeated-measures analysis adjusted for
baseline PRI values showed that the LD group had
signiﬁcantly lower PRI levels compared with the MD
group (ANCOVA, p ¼ 0.031) (Online Figure 1). PRI
levels at 1 h were not signiﬁcantly different between
groups (p ¼ 0.117), whereas the PRI levels at 4 h were
signiﬁcantly lower in the LD group compared with the
MD group (p ¼ 0.012) (Online Figure 1).
Intragroup comparisons in the MD group showed a
nonsigniﬁcant reduction in PRI over time (ANOVA,
p ¼ 0.206) (Figure 2A); there were no intragroup
differences between time points (baseline vs 1 h,
p ¼ 0.931; baseline vs. 4 h, p ¼ 0.318; 1 h vs. 4 h,
FIGURE 1 Subject Disposition
LD ¼ loading dose; MD ¼ maintenance dose.
TABLE 1 Baseline Characteristics
Ticagrelor 90 mg
(n ¼ 30)
Ticagrelor 180 mg
(n ¼ 30) p Value
Age, yrs 57.97  7.92 55.80  7.41 0.277
Male 22 (73.3) 22 (73.3) >0.999
BMI, kg/m2 29.33  4.02 29.02  5.50 0.803
Race 0.599
Caucasian 20 (66.7) 21 (70)
African American 9 (30) 9 (30)
Hispanic 1 (3.3) 0
Hypertension 26 (86.7) 28 (93.3) 0.671
Dyslipidemia 26 (86.7) 29 (96.7) 0.353
Smoking 6 (20) 6 (20) >0.999
Diabetes mellitus 8 (26.7) 5 (16.7) 0.532
Medications*
Beta-blocker 28 (93.3) 27 (90.0) >0.999
ACEI/ARB 21 (70) 24 (80) 0.552
Statins 30 (100) 30 (100) >0.999
PPI 6 (20) 3 (10) 0.472
CCB 2 (6.7) 2 (6.7) >0.999
Nitrate 8 (26.7) 8 (26.7) >0.999
LVEF, % 56  12 55  12 0.571
Creatinine clearance,
ml/min
110  27 108.3  29 0.742
Hematocrit 38.7  3.7 39  4.3 0.823
Platelet count,
1,000/mm3
249.2  104 233.9  69.2 0.505
PCI† 27 (90) 28 (93) >0.999
Maintenance therapy
duration, days‡
20.5 (17.0–25.2) 26.5 (18.7–33.7) 0.053
Values are mean  SD, n (%), or median (interquartile range). *All patients
on aspirin 81 mg/day and ticagrelor 90 mg twice daily. †Most (91.7%) patients
treated with PCI at time of acute coronary syndrome presentation; 8.3%
of patients medically managed after undergoing invasive evaluation. ‡Time
frame between ﬁrst ticagrelor dose after the acute event and ﬁrst study
blood draw.
ACEI/ARB ¼ angiotensin-converting enzyme inhibitors/angiotensin receptor
blocker; BMI ¼ body mass index; CCB ¼ calcium channel blocker; LVEF ¼ left
ventricular ejection fraction; PCI ¼ percutaneous coronary intervention; PPI ¼
proton pump inhibitor.
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1078p > 0.999) (Figure 2A). Intragroup comparisons in the
LD group showed a signiﬁcant decrease in PRI levels
over time (ANOVA, p < 0.001) (Figure 2B). PRI values
at 1 h (p ¼ 0.011) and 4 h (p ¼ 0.001) were markedly
reduced compared with PRI levels at baseline,
whereas there were no signiﬁcant differences be-
tween 1 and 4 h (p ¼ 0.666) (Figure 2B).
Ver i fyNow P2Y12 assay . P2Y12 react ion un i ts .
There were no signiﬁcant differences in baseline PRU
between groups (p ¼ 0.448). In the intergroup com-
parison adjusted for baseline value, PRU values were
signiﬁcantly reduced in the LD group compared with
the MD group during the overall time course
(ANCOVA, p ¼ 0.026) (Online Figure 2). At 1 h, PRU
levels were nonsigniﬁcantly lower in the LD group
compared with the MD group (p ¼ 0.128), but were
signiﬁcantly reduced at 4 h (p ¼ 0.006) (Online
Figure 2).
Intragroup comparison in the MD group showed
that PRU levels signiﬁcantly decreased over time
(ANOVA, p ¼ 0.019) (Figure 3A). PRU values were
signiﬁcantly reduced compared with baseline only at
4 h (p ¼ 0.033), but not at 1 h (p ¼ 0.113) (Figure 3A).
Intragroup comparisons in the LD group showed that
PRU levels signiﬁcantly decreased over time (ANOVA,
p < 0.001) (Figure 3B), with a signiﬁcant decrease
already at 1 h (p ¼ 0.001), which was sustained at 4 h
(p < 0.001), without signiﬁcant changes between 1
and 4 h (p ¼ 0.317) (Figure 3B).
Light transmittance aggregometry. There were no sig-
niﬁcant differences in baseline ADP-induced platelet
aggregation between groups (p ¼ 0.213). The adjustedintergroup comparison showed a signiﬁcant reduc-
tion of ADP-induced platelet aggregation in the LD
group compared with the MD group during the overall
time course (ANCOVA, p ¼ 0.004) (Online Figure 3).
Intergroup comparisons showed a nonsigniﬁcant
reduction in ADP-induced platelet aggregation in the
LD group compared with the MD group at 1 h (p ¼
0.155), which reached statistical signiﬁcance at 4 h
(p < 0.001) (Online Figure 3).
Intragroup comparison in the MD group showed
that ADP-induced platelet aggregation signiﬁcantly
decreased over time (ANOVA, p < 0.001) (Figure 4A).
ADP-induced platelet aggregation was signiﬁcantly
reduced compared with baseline at 1 h (p < 0.001)
and 4 (p ¼ 0.001) h (Figure 4A). Intragroup com-
parisons in the LD group showed that ADP-induced
platelet aggregation signiﬁcantly decreased over
FIGURE 2 Intragroup Comparisons of Platelet Reactivity Index Across Time Points
(A) Intragroup comparisons of whole-blood vasodilator-stimulated phosphoprotein platelet reactivity index (VASP-PRI) across time points in
the ticagrelor 90 mg group. (B) Intragroup comparisons of VASP-PRI across time points in the ticagrelor 180 mg group. Data are presented as
least square means. Error bars indicate SE. Analysis of variance (ANOVA) p value refers to the overall difference in VASP-PRI in each group. The
p values are provided for intragroup comparisons between each time points.
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1079time (ANOVA, p < 0.001) (Figure 4B), with a signiﬁ-
cant decrease at 1 h (p ¼ 0.011) which was sustained
at 4 h (p ¼ 0.001) (Figure 4B).
DISCUSSION
The need for coronary revascularization despite being
compliant with P2Y12-inhibiting therapy may occur
for a variety of reasons, including treatment failureFIGURE 3 Intragroup Comparisons of P2Y12 Reaction Units Across T
(A) Intragroup comparisons of VerifyNow P2Y12 reaction units (VN-PRU)
comparisons of VN-PRU across time points in the ticagrelor 180 mg gro
Analysis of variance (ANOVA) p value refers to the overall difference in
comparisons between each time points.with the occurrence of an acute ischemic event, the
need for a staged PCI, or progression of coronary
atherosclerotic disease (9–11). This therefore raises a
clinical question with regard to the dosing regimen of
a P2Y12-inhibiting agent to be used in a patient on
maintenance DAPT therapy. To date, investigations
assessing dosing regimens of P2Y12 receptor inhibitors
in patients on maintenance therapy have been limited
to thienopyridines but not the nonthienopyridineime Points
across time points in the ticagrelor 90 mg group. (B) Intragroup
up. Data are presented as least square means. Error bars indicate SE.
VN-PRU in each group. The p values are provided for intragroup
FIGURE 4 Intragroup Comparisons of ADP-Induced Platelet Aggregation Across Time Points
(A) Intragroup comparisons of ADP 20 mM-induced platelet aggregation measured by light transmission aggregometry (LTA) across time points in the ticagrelor
90 mg group. (B) Intragroup comparisons of ADP 20 mM-induced platelet aggregation measured by LTA across time points in the ticagrelor 180 mg group. Data are
presented as least square means. Error bars indicate SE. Analysis of variance (ANOVA) p value refers to the overall difference in platelet aggregation in each group. The
p values are provided for intragroup comparisons between each time points.
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1080ticagrelor (12–17). We therefore conducted a study to
address the impact of 2 different ticagrelor dosing
regimens in patients on a standard 90-mg bid main-
tenance therapy. Our PD investigation showed that
compared with a 90-mg dose, a 180-mg reloading dose
of ticagrelor is associated with enhanced platelet in-
hibition in patients on maintenance therapy.
Furthermore, enhanced platelet inhibitory effects
were achieved promptly with this regimen. Impor-
tantly, consistent ﬁndings were observed using 3
different PD assays.
Currently, practice guidelines provide limited rec-
ommendations with regard to the management of
patients already on maintenance P2Y12 receptor–
inhibiting therapy undergoing PCI or presenting with
an ACS (1–3). Various studies have been conducted to
assess the impact of different dosing regimens of
P2Y12 receptor inhibitors, either reloading with the
same agent or switching therapy, in patients on
maintenance therapy (20). A $600-mg LD of clopi-
dogrel has been shown to reduce residual platelet
reactivity in patients on long-term clopidogrel ther-
apy, as well as decrease peri-PCI ischemic complica-
tions, particularly in ACS patients (12–14). The fact
that clopidogrel therapy is associated with only
modest P2Y12 receptor occupancy explains why
switching to either prasugrel or ticagrelor leads
to further platelet blockade (21–26). Importantly,
although randomized studies speciﬁcally designed toassess the clinical impact of switching from clopi-
dogrel to a novel P2Y12 receptor inhibitor are lacking,
nearly one-half the patients randomized to ticagrelor
in the landmark PLATO (Study of Platelet Inhibition
and Patient Outcomes) trial were pre-treated with
clopidogrel, showing consistent ﬁndings with the
overall trial results (27). Moreover, many registries
have supported the efﬁcacy and safety of switching
from clopidogrel to prasugrel (28–31).
The PD impact of administering escalating prasu-
grel dosing regimens in patients on standard main-
tenance therapy has been recently reported,
demonstrating that a 60-mg LD of prasugrel induces
more prompt and potent reduction in platelet reac-
tivity, with better response proﬁles, compared with
lower dosing regimens (15,16). These study ﬁndings
also suggest that maintenance therapy with a potent
P2Y12–inhibiting agent such as prasugrel still leaves
a considerable number of P2Y12 receptors uninhib-
ited. This is in line with in vitro and ex vivo PD
investigations using cangrelor in which residual
P2Y12-mediated signaling in patients on maintenance
prasugrel therapy is virtually abolished (32,33).
However, ticagrelor has several pharmacological dif-
ferences compared with thienopyridines. In partic-
ular, ticagrelor is direct acting with reversible binding
and has a plasma half-life of 6 to 13 h requiring twice-
daily administration to maintain steady-state levels
of platelet inhibition (4–7). In contrast to the
PERSPECTIVES
WHAT IS KNOWN? Ticagrelor is a new-generation P2Y12
receptor inhibitor associated with better clinical outcomes
compared with clopidogrel. However, many patients on
maintenance P2Y12-inhibiting therapies, including ticagrelor, may
need to undergo coronary revascularization procedures, raising a
common clinical question with regard to the dosing regimen to
be used.
WHAT IS NEW? Our study ﬁndings demonstrate that in pa-
tients on standard maintenance ticagrelor therapy, a 180-mg
reloading dose achieves more prompt and potent P2Y12 inhibition
compared with a 90-mg dosing regimen as assessed by multiple
pharmacodynamic assessments.
WHAT IS NEXT? Because enhanced platelet inhibition in the
periprocedure period reduces ischemic events, larger studies are
needed to support the clinical impact of these pharmacodynamic
ﬁndings.
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1081thienopyridines, which require LD regimens that are
several fold higher than their MD (e.g., 4- to 8-fold
higher for clopidogrel and 6-fold higher for prasu-
grel), the LD of ticagrelor is the same as the total daily
MD. Therefore, although the enhanced PD differences
observed with LD regimens of thienopyridines may be
intuitive, this is less obvious for ticagrelor and pro-
vides further support for the rationale of our
investigation.
CLINICAL IMPLICATIONS. Although our study was
not designed to assess clinical outcomes, there are
potential clinical implications of this investigation. In
fact, achieving enhanced platelet inhibition in the
peri-PCI period reduces ischemic events, in particular
when optimizing blockade of the P2Y12 receptor
signaling pathway (34,35). This is supported by
large-scale clinical trial data showing a signiﬁcant
reduction in myocardial infarction and stent throm-
bosis in the peri- and post-PCI period associated
with the potent P2Y12 receptor inhibitor cangrelor
(36–38). Our study ﬁndings clearly demonstrate
more prompt and potent P2Y12 inhibition when a
180-mg reloading dose of ticagrelor is administered
to patients on maintenance therapy. In turn, this
also indicates that uninhibited P2Y12 receptors
persist on the platelet membrane of patients while
on maintenance therapy. This observation is also
supported by ex vivo PD investigations conducted in
ticagrelor-treated patients in which residual P2Y12-
mediated signaling is markedly reduced by cangrelor
(39). Importantly, uninhibited P2Y12 receptors may
represent a pathway for circulating ADP, released
during an acute ischemic event or during a revas-
cularization procedure, to activate platelets and lead
to a periprocedural ischemic complication. There-
fore, administration of a 180-mg LD of ticagrelor
may be a more optimal strategy than using a 90-mg
dose in patients on maintenance therapy requiring
PCI or presenting with an acute coronary event. It
may be argued that in another study, there were
no PD differences between a 90-mg and a 180-mg
dose in clopidogrel-treated patients (40). However,
this study was conducted in patients with optimal
response to clopidogrel, which may have limited
the ability to see a treatment effect and was in
contrast with a more detailed PD investigation
that demonstrated enhanced platelet inhibitory
effects of a 180-mg LD irrespective of clopidogrel
responsiveness (25).
STUDY LIMITATIONS. This investigation was pow-
ered to assess intragroup comparisons but not inter-
group comparisons. Therefore, the latter resultsshould be considered as exploratory. In addition, our
study was conducted in patients who were clinically
stable after experiencing an ACS and not in patients
undergoing PCI who may therefore share different PD
proﬁles. Moreover, our study was not powered to
assess safety or efﬁcacy, which would require larger
clinical studies. Hence, the lack of adverse events,
including bleeding complications (e.g., arterial access
site complications), in this study should be inter-
preted with caution.CONCLUSIONS
In patients on maintenance ticagrelor therapy, a
180-mg LD of ticagrelor is associated with more
prompt and potent PD effects compared with a 90-mg
dosing regimen. Although the clinical implications of
our PD study ﬁndings remain to be demonstrated,
achieving enhanced P2Y12 receptor blockade in the
peri-PCI period is well established to reduce ischemic
events, suggesting the use of a 180-mg reloading dose
of ticagrelor in patients on maintenance therapy
when undergoing PCI. Clinical outcomes studies are
warranted to support these PD ﬁndings.
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